



HARVARD BIOSCIENCE

[Overview](#) | [Corporate Governance](#) | [Stock Quote](#) |
[Stock Chart](#) | [Press Releases](#) | [Pro Forma Reconciliation](#) |
[Guidance](#) | [Financial Reports](#) | [Analysts](#) | [SEC Filings](#) | [FAQ](#)
[| Email Alerts](#) | [Info Request](#) |
[Archived Presentations & Webcasts](#)

Harvard Bioscience, Inc. (ticker: HBIO, exchange: NASDAQ) News Release - Jun-9-2004

HBIO President Adopts 10b5-1 Plan

HOLLISTON, Mass.--(BUSINESS WIRE)--June 9, 2004-- Harvard Bioscience, Inc., (Nasdaq: HBIO) today announced that its president, David Green, has established a stock-trading plan in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Rule 10b5-1 plans permit directors and officers who are not in possession of material, non-public information to establish prearranged plans to buy or sell company stock. Once the plan is in place, the executive does not retain or exercise any discretion over shares traded under the plan, although the executive may later amend or terminate the plan. The broker administering the plan is authorized to trade company shares in volumes and at times determined independently by the broker, subject to the limitations set forth in the plan. Using these plans, insiders can: diversify their investment portfolios; spread stock trades over a period of time to reduce any market impact; and avoid concerns about whether they had material, non-public information when they sold their stock.

This plan has been established in order for Mr. Green to gain liquidity in an orderly, prearranged manner. The plan provides for the sale of less than 20 percent of his holdings of Harvard Bioscience stock over a period of approximately eighteen months. The transactions under this plan will be disclosed publicly through Form 144 and Form 4 filings with the Securities and Exchange Commission.

The plan was adopted during an authorized trading period at a time when Mr. Green was not in possession of material, non-public information.

About Harvard Bioscience

Harvard Bioscience is a global developer, manufacturer and marketer of innovative, enabling tools in drug discovery research at pharmaceutical and biotechnology companies, universities and government laboratories. HBIO sells its products to thousands of researchers in 100 countries through its direct sales force, its 1,100 page catalog, various specialty catalogs and through its distributors, including Amersham Biosciences, Fisher Scientific and ColeParmer. HBIO has sales and manufacturing operations in the United States, the United Kingdom, Belgium, Austria and Germany with sales facilities in France and Canada. For more information please visit www.harvardbioscience.com.

The statements made in this press release that are not statements of historical fact are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements or inferences about Mr. Green's ability to sell shares of the Company's common stock, management's confidence or expectations, and the Company's plans, objectives and intentions that are not historical facts. Factors that may cause the Company's actual results, performance or achievements to differ materially from those in the forward-looking statements include, but are not limited to, those factors set forth under the heading "Important Factors That May Affect Future Operating Results" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2003, as well as other risks described in the Company's public filings or factors, if any, of which the Company is not currently aware. The Company may not update these forward-looking statements, even though its situation may change in the future, unless it has obligations under the Federal securities laws to update and disclose material developments related to previously disclosed information.

CONTACT: Harvard Bioscience, Inc
David Green, 508-893-8999
dgreen@harvardbioscience.com

SOURCE: Harvard Bioscience, Inc.